Evidence map›Paper›PMID 27234478›Full record

Observational studyJournal of medical systems2016

Identification of Major Adverse Kidney Events Within the Electronic Health Record.

Matthew W Semler, Todd W Rice, Andrew D Shaw, Edward D Siew, Wesley H Self, Avinash B Kumar, Daniel W Byrne, Jesse M Ehrenfeld, Jonathan P Wanderer

2 registry-linked trialsAbstract readObservational Study
In one paragraph

Observational study in Journal of medical systems, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05590143 phase4active not recruitingnot on this mapstarted 2023, after this paper: background citation

Preoperative Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Postoperative Acute Kidney Injury in Cardiac Surgery Patients - a Randomized, Placebo-controlled, Multi-centre, Phase IV Clinical Trial

TypeinterventionalSponsorAmsterdam UMCRan2023 to 2025Enrolled784ConditionsAcute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 InhibitorArmsDapagliflozin 10 MG Oral Tablet [Farxiga], Placebo
NCT05898126 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Personalized Hemodynamic Management Based on Serum Renin Concentration on Acute Kidney Injury Progression in Patients With Shock: a Randomized Controlled Trial.

TypeinterventionalSponsorUniversità Vita-Salute San RaffaeleRan2025 to 2027Enrolled800ConditionsShockArmsRenin-guided hemodynamic management, Usual care
3 · Its place in the literature

Who cites it

51 citing papers in PubMed.

  1. Trial
  2. Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial.American journal of respiratory and critical care medicine · 2019
    Trial
  3. Balanced Crystalloids versus Saline in Noncritically Ill Adults.The New England journal of medicine · 2018
    Trial
  4. Balanced Crystalloids versus Saline in Critically Ill Adults.The New England journal of medicine · 2018
    Trial
  5. Balanced Crystalloids versus Saline in the Intensive Care Unit. The SALT Randomized Trial.American journal of respiratory and critical care medicine · 2017
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew W SemlerDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Ave S., T-2220 MCN, Nashville, TN, 37232-2650, USA. matthew.w.semler@vanderbilt.edu.
Todd W RiceDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Ave S., T-2220 MCN, Nashville, TN, 37232-2650, USA.
Andrew D ShawDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Edward D SiewDivision of Nephrology and Hypertension, Vanderbilt Center for Kidney Disease (VCKD) and Integrated Program for AKI (VIP-AKI), Vanderbilt University Medical Center, Nashville, TN, USA.
Wesley H SelfDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Avinash B KumarDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Daniel W ByrneDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Jesse M EhrenfeldDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jonathan P WandererDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Clinical and Translational Training Program in Pulmonary MedicineT32HL087738 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lorraine B Ware · 2007 to 2026
$7.0M
Salivary Cortisol as a Marker of Community-Acquired Pneumonia Severity in AdultsK23GM110469 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SELF, WESLEY H · 2015 to 2018
$683k
HSRD VA IIR 13-073NCATS NIH HHS UL1 TR000445NHLBI NIH HHS T32 HL087738NIGMS NIH HHS K23 GM110469
6 · The paper itself

Abstract

Acute kidney injury is common among critically ill adults and is associated with increased mortality and morbidity. The Major Adverse Kidney Events by 30 days (MAKE30) composite of death, new renal replacement therapy, or persistent renal dysfunction is recommended as a patient-centered outcome for pragmatic trials involving acute kidney injury. Accurate electronic detection of the MAKE30 endpoint using data within the electronic health record (EHR) could facilitate the use of the EHR in large-scale kidney injury research. In an observational study using prospectively collected data from 200 admissions to a single medical intensive care unit, we tested the performance of electronically-extracted data in identifying the MAKE30 composite compared to the reference standard of two-physician manual chart review. The incidence of MAKE30 on manual-review was 16 %, which included 8.5 % for in-hospital mortality, 3.5 % for new renal replacement therapy, and 8.5 % for persistent renal dysfunction. There was strong agreement between the electronic and manual assessment of MAKE30 (98.5 % agreement [95 % CI 96.5-100.0 %]; kappa 0.95 [95 % CI 0.87-1.00]; P < 0.001), with only three patients misclassified by electronic assessment. Performance of the electronic MAKE30 assessment was similar among patients with and without CKD and with and without a measured serum creatinine in the 12 months prior to hospital admission. In summary, accurately identifying the MAKE30 composite outcome using EHR data collected as a part of routine care appears feasible.

Indexed as

Acute Kidney InjuryAdultAgedAge FactorsBlack or African AmericanCreatinineElectronic Health RecordsFemaleHospital MortalityHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesRenal InsufficiencyRenal Replacement TherapyCreatinineAcute kidney injuryElectronic health recordIntensive care unitMajor adverse kidney events

Identifiers

PMID27234478
PMCPMC5791539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.